Navigation Links
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Date:11/15/2011

AMSTERDAM, November 16, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency (EMA) has granted orphan designation for its gene therapy program for the treatment of hemophilia B. Orphan designation in the European Union provides several benefits including 10 years of market exclusivity from product launch and access to the central authorization procedure.

AMT's hemophilia B program, which consists of an adeno-associated viral (AAV) vector containing the human factor IX gene, is being investigated in a Phase I/II study conducted by St. Jude's Children's Research Hospital (Memphis, USA) and University College London (UK). Promising data from an initial 6 patients shows that gene therapy administration resulted in a reduced need for protein replacement treatment, the standard care for hemophilia patients.  AMT is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.

"Orphan designation is an important milestone for our hemophilia B gene therapy program and will provide additional support to our negotiations as we seek potential licensing partners," said Jörn Aldag, CEO of AMT. "A successful gene therapy for hemophilia could dramatically change not only the lives of patients but also the current hemophilia market that is dominated by protein replacement therapies."  

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to desi
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
2. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
3. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
4. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
5. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
6. GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
7. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Molecular Devices Launches the MicroMax Low Volume Microplate, the Highest Throughput Low Volume Solution Available
10. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
11. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s ... about some of our Medicare resources and continue highlighting the success of the prescription ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... SUNNYVALE, Calif., Oct. 24, 2011 Accuray Incorporated (Nasdaq: ... that it will report results for its first quarter of ... 8, 2011 after the market closes. A conference ... fiscal year 2012 will begin at 2:00 p.m. PST/5:00 p.m. ...
... Awarepoint Corporation , the leading provider of ... the hiring of four senior management executives to support ... solutions in hospitals and clinics. Merrie Wallace, R.N., B.S.N., ... solutions, reporting to Awarepoint CEO Jay Deady. Chris Cosgrove ...
Cached Medicine Technology:Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2012 2Awarepoint Expands Senior Management Team 2Awarepoint Expands Senior Management Team 3
(Date:7/31/2015)... ... , ... Transfinder, a software company based in Schenectady, N.Y., achieved record revenue ... for the first six months ended June 30, 2015 compared with the same period ... year’s record-revenue mark of $10.4 million. , “We know what our customers need and ...
(Date:7/31/2015)... ... 2015 , ... The Mount Sinai Health System will work with Columbia Care ... related, experimental treatments. The collaboration moves into the next phase with the recent decision ... five state licenses to produce and dispense medical marijuana. , Mount Sinai and ...
(Date:7/31/2015)... Falls Church, VA (PRWEB) , ... July 31, ... ... the Way, Oct. 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having ... But it doesn’t have to. , Instead of risking containment — or even ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Patients with higher ... to a study published today in Nature Communications and led by researchers from the ... suggests that variations in the gene RTN1 led to greater production of the related ...
(Date:7/31/2015)... ... ... Down is a reputable source of authentic USA vs. Australia tickets at Ford ... National Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World ... team was awarded the Golden Ball as the best player of the 2015 Women's World ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... coverage and access to health care , , FRIDAY, Jan. ... insurance and no regular source of health care are the ... University of Michigan C.S. Mott Children,s Hospital report. , The ... safeguard the health of vulnerable children, said the researchers, who ...
... Global Telemedicine Inc., supplies medical peripherals to the successful installations of ... advancing telemedicine program , ... N. Chelmsford, MA (PRWEB) ... Telemedicine has worked closely with Texas Tech University Health ...
... Jan. 30 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc. (NYSE ... Chinese medicine ("TCM") based in Chengdu, China,today announced ... of shares,under its previously announced stock repurchase program. ... reducing the number of outstanding shares of its,common ...
... BOSTON, Jan. 30 Neurosilicon,s novel Photoconductive Stimulation Device ... Hung and Colicos titled, Astrocytic Ca2+ Waves Guide CNS ... article appearing in the November 2008 issue of The ... role of neuronal activity in mediating axonal guidance. It ...
... IDEXX Laboratories, Inc. (Nasdaq: IDXX ), ... 2008 were $243.3 million compared to $245.0 million for ... is reported growth adjusted to eliminate the effect of ... businesses acquired, divested or discontinued since October 1, 2007, ...
... ("QLT") (NASDAQ: QLTI ; TSX: QLT) announced the ... "Offer"), which expired at 5:00 p.m. (Eastern time) on January ... 20,000,000 of its common shares (the "Shares") at a price ... million. The purchased Shares represent approximately 26.8% of the Shares ...
Cached Medicine News:Health News:Medical Needs of 6.2 Million U.S. Kids Go Unmet 2Health News:Texas Tech University Health Sciences Center and AMD Global Telemedicine Inc. Expand Telemedicine Program Throughout Texas 2Health News:Texas Tech University Health Sciences Center and AMD Global Telemedicine Inc. Expand Telemedicine Program Throughout Texas 3Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 2Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 3Health News:Novel Photoconductive Cellular Depolarization Technology Reveals Insight Into Neuronal Growth, Guidance, and Regeneration 2Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 2Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 3Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 4Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 5Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 6Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 7Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 8Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 9Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 10Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 11Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 12Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 13Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 14Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 15Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 16Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 17Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 18Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 19Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 20Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 21Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 22Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 23Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 24Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 25Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 26Health News:QLT announces final results of tender offer 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: